Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system

被引：10
作者：
Yoon, Esther C. [1 ]
Schwartz, Christopher [1 ]
Brogi, Edi [2 ]
Ventura, Katia [2 ]
Wen, Hannah [2 ]
Darvishian, Farbod [1 ]
机构：
[1] NYU, Dept Pathol, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
来源：
BREAST JOURNAL | 2019年 / 25卷 / 05期
关键词：
21-gene recurrence score assay; American Joint Committee on Cancer; biomarkers; breast cancer; estrogen receptor; human epidermal growth factor receptor 2; OncotypeDx (TM); progesterone receptor; prognosis; staging; DX RECURRENCE SCORE; AMERICAN JOINT COMMITTEE; ESTROGEN-RECEPTOR; VALIDATION; ASSAY; CARCINOMA; RECOMMENDATIONS; EXPRESSION; SOCIETY; PREDICT;
D O I：
10.1111/tbj.13352
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The 8th edition of the American Joint Committee on Cancer (AJCC) staging guidelines combine traditional TNM system with biomarkers to reflect our current understanding of tumor biology and targeted therapy. In this study, we investigated the impact of the TNM + Biomarkers staging system and the additive value of Oncotype Dx (TM) genomic profile recurrence score (RS) (TNM + Biomarkers+RS <11) for the staging of breast cancer (BC) using data from two tertiary referral cancer centers. Compared to TNM alone, the TNM + Biomarkers system changed the stage group in 32.7% of BCs (27% downstage, 5.7% upstage). Most (98.3%) of the downstaged BCs were estrogen receptor (ER)+/progesterone receptor (PR)+, whereas 78% of the upstaged BCs were ER-/PR-/human epidermal growth factor receptor 2 (HER2)-. Compared to TNM + Biomarkers staging, the addition of genetic profile data (TNM + Biomarker+RS <11) downstaged only <1% BCs. Our analysis suggests that for T1-T2N0 ER+/HER2- BCs, Oncotype Dx (TM) RS <11 provides added value as a staging parameter only in a very small group of cases compared to TNM + Biomarkers alone.
引用
收藏
页码：829 / 837
页数：9
相关论文
共 43 条
[21]  
Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48
[22]   American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer [J].
Harris, Lyndsay ;
Fritsche, Herbert ;
Mennel, Robert ;
Norton, Larry ;
Ravdin, Peter ;
Taube, Sheila ;
Somerfield, Mark R. ;
Hayes, Daniel F. ;
Bast, Robert C., Jr. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5287-5312
[23]  
Hou YJ, 2017, AM J CLIN PATHOL, V147, P541, DOI [10.1093/AJCP/AQX008, 10.1093/ajcp/aqx008]
[24]  
Hu Hui, 2017, World J Oncol, V8, P71, DOI 10.14740/wjon1039e
[25]   Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis [J].
Klein, Molly E. ;
Dabbs, David J. ;
Shuai, Yongli ;
Brufsky, Adam M. ;
Jankowitz, Rachel ;
Puhalla, Shannon L. ;
Bhargava, Rohit .
MODERN PATHOLOGY, 2013, 26 (05) :658-664
[26]   A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer [J].
Lee, Sae Byul ;
Sohn, Guiyun ;
Kim, Jisun ;
Chung, Il Yong ;
Lee, Jong Won ;
Kim, Hee Jeong ;
Ko, Beom Seok ;
Son, Byung Ho ;
Ahn, Sei-Hyun .
BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (02) :257-266
[27]   The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong [J].
Leung, Roland C. Y. ;
Yau, Thomas C. C. ;
Chan, Miranda C. M. ;
Chan, Sharon W. W. ;
Chan, Terence W. C. ;
Tsang, Yvonne Y. Y. ;
Wong, Ting Ting ;
Chao, Calvin ;
Yoshizawa, Carl ;
Soong, Inda S. ;
Kwan, Wing-Hong ;
Kwok, Carol C. H. ;
Suen, Joyce S. J. ;
Ngan, Roger K. C. ;
Cheung, Polly S. Y. .
CLINICAL BREAST CANCER, 2016, 16 (05) :372-378
[28]   Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology [J].
Mittendorf, Elizabeth A. ;
Chavez-MacGregor, Mariana ;
Vila, Jose ;
Yi, Min ;
Lichtensztajn, Daphne Y. ;
Clarke, Christina A. ;
Giordano, Sharon H. ;
Hunt, Kelly K. .
ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (12) :3502-3509
[29]   The assessment of HER2 status in breast cancer: the past, the present, and the future [J].
Nitta, Hiroaki ;
Kelly, Brian D. ;
Allred, Craig ;
Jewell, Suzan ;
Banks, Peter ;
Dennis, Eslie ;
Grogan, Thomas M. .
PATHOLOGY INTERNATIONAL, 2016, 66 (06) :313-324
[30]   Triple-negative breast cancer: The importance of molecular and histologic subtyping, and recognition of low-grade variants [J].
Pareja F. ;
Geyer F.C. ;
Marchiò C. ;
Burke K.A. ;
Weigelt B. ;
Reis-Filho J.S. .
npj Breast Cancer, 2 (1)
12345